Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 301

1.

Stereotactic Body Radiation Therapy as an Alternative Treatment for Patients with Hepatocellular Carcinoma Compared to Sorafenib: A Propensity Score Analysis.

Bettinger D, Pinato DJ, Schultheiss M, Sharma R, Rimassa L, Pressiani T, Burlone ME, Pirisi M, Kudo M, Park JW, Buettner N, Neumann-Haefelin C, Boettler T, Abbasi-Senger N, Alheit H, Baus W, Blanck O, Gerum S, Guckenberger M, Habermehl D, Ostheimer C, Riesterer O, Tamihardja J, Grosu AL, Thimme R, Brunner TB, Gkika E.

Liver Cancer. 2019 Jul;8(4):281-294. doi: 10.1159/000490260. Epub 2018 Jul 12. Erratum in: Liver Cancer. 2019 Jul;8(4):295.

PMID:
31602371
2.

Automatic Tumor Segmentation With a Convolutional Neural Network in Multiparametric MRI: Influence of Distortion Correction.

Bielak L, Wiedenmann N, Henrik Nicolay N, Lottner T, Fischer J, Bunea H, Grosu AL, Bock M.

Tomography. 2019 Sep;5(3):292-299. doi: 10.18383/j.tom.2019.00010.

3.

Prostate-specific Membrane Antigen Positron Emission Tomography-detected Oligorecurrent Prostate Cancer Treated with Metastases-directed Radiotherapy: Role of Addition and Duration of Androgen Deprivation.

Kroeze SGC, Henkenberens C, Schmidt-Hegemann NS, Vogel MME, Kirste S, Becker J, Burger IA, Derlin T, Bartenstein P, Eiber M, Mix M, la Fougère C, Christiansen H, Belka C, Combs SE, Grosu AL, Müller AC, Guckenberger M.

Eur Urol Focus. 2019 Sep 5. pii: S2405-4569(19)30270-6. doi: 10.1016/j.euf.2019.08.012. [Epub ahead of print]

PMID:
31495759
4.

Mesenchymal stem cells preserve their stem cell traits after exposure to antimetabolite chemotherapy.

Lopez Perez R, Münz F, Vidoni D, Rühle A, Trinh T, Sisombath S, Zou B, Wuchter P, Debus J, Grosu AL, Saffrich R, Huber PE, Nicolay NH.

Stem Cell Res. 2019 Aug 13;40:101536. doi: 10.1016/j.scr.2019.101536. [Epub ahead of print]

5.

Validation of different PSMA-PET/CT-based contouring techniques for intraprostatic tumor definition using histopathology as standard of reference.

Zamboglou C, Fassbender TF, Steffan L, Schiller F, Fechter T, Carles M, Kiefer S, Rischke HC, Reichel K, Schmidt-Hegemann NS, Ilhan H, Chirindel AF, Nicolas G, Henkenberens C, Derlin T, Bronsert P, Mavroidis P, Chen RC, Meyer PT, Ruf J, Grosu AL.

Radiother Oncol. 2019 Aug 17. pii: S0167-8140(19)32981-0. doi: 10.1016/j.radonc.2019.07.002. [Epub ahead of print]

PMID:
31431386
6.

Estimation of the α/β ratio of non-small cell lung cancer treated with stereotactic body radiotherapy.

Klement RJ, Sonke JJ, Allgäuer M, Andratschke N, Appold S, Belderbos J, Belka C, Dieckmann K, Eich HT, Flentje M, Grills I, Eble M, Hope A, Grosu AL, Semrau S, Sweeney RA, Hörner-Rieber J, Werner-Wasik M, Engenhart-Cabillic R, Ye H, Guckenberger M.

Radiother Oncol. 2019 Aug 17. pii: S0167-8140(19)32998-6. doi: 10.1016/j.radonc.2019.07.008. [Epub ahead of print]

PMID:
31431371
7.

[68Ga-]PSMA-11 PET/CT and multiparametric MRI for gross tumor volume delineation in a slice by slice analysis with whole mount histopathology as a reference standard - Implications for focal radiotherapy planning in primary prostate cancer.

Bettermann AS, Zamboglou C, Kiefer S, Jilg CA, Spohn S, Kranz-Rudolph J, Fassbender TF, Bronsert P, Nicolay NH, Gratzke C, Bock M, Ruf J, Benndorf M, Grosu AL.

Radiother Oncol. 2019 Aug 17. pii: S0167-8140(19)32984-6. doi: 10.1016/j.radonc.2019.07.005. [Epub ahead of print]

PMID:
31431366
8.

Interference of tumour mutational burden with outcome of patients with head and neck cancer treated with definitive chemoradiation: a multicentre retrospective study of the German Cancer Consortium Radiation Oncology Group.

Eder T, Hess AK, Konschak R, Stromberger C, Jöhrens K, Fleischer V, Hummel M, Balermpas P, von der Grün J, Linge A, Lohaus F, Krause M, Baumann M, Stuschke M, Zips D, Grosu AL, Abdollahi A, Debus J, Belka C, Pigorsch S, Combs SE, Budach V, Tinhofer I; DKTK-ROG.

Eur J Cancer. 2019 Jul;116:67-76. doi: 10.1016/j.ejca.2019.04.015. Epub 2019 Jun 4.

PMID:
31173964
9.

Randomized Phase II Trial of Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: CAO/ARO/AIO-12.

Fokas E, Allgäuer M, Polat B, Klautke G, Grabenbauer GG, Fietkau R, Kuhnt T, Staib L, Brunner T, Grosu AL, Schmiegel W, Jacobasch L, Weitz J, Folprecht G, Schlenska-Lange A, Flentje M, Germer CT, Grützmann R, Schwarzbach M, Paolucci V, Bechstein WO, Friede T, Ghadimi M, Hofheinz RD, Rödel C; German Rectal Cancer Study Group.

J Clin Oncol. 2019 May 31:JCO1900308. doi: 10.1200/JCO.19.00308. [Epub ahead of print]

PMID:
31150315
10.

Remodelling in atrial fibrillation: the impact of amiodarone.

Grosu AI, Radulescu D, Grosu LC, Pop D.

Cardiovasc J Afr. 2019 May/Jun 23;30(3):174-180. doi: 10.5830/CVJA-2019-012. Epub 2019 Mar 27. Review.

11.

Radiomic features from PSMA PET for non-invasive intraprostatic tumor discrimination and characterization in patients with intermediate- and high-risk prostate cancer - a comparison study with histology reference.

Zamboglou C, Carles M, Fechter T, Kiefer S, Reichel K, Fassbender TF, Bronsert P, Koeber G, Schilling O, Ruf J, Werner M, Jilg CA, Baltas D, Mix M, Grosu AL.

Theranostics. 2019 Apr 13;9(9):2595-2605. doi: 10.7150/thno.32376. eCollection 2019.

12.

Neuroimaging for Radiation Therapy of Brain Tumors.

Popp I, Weber WA, Combs SE, Yuh WTC, Grosu AL.

Top Magn Reson Imaging. 2019 Apr;28(2):63-71. doi: 10.1097/RMR.0000000000000198. Review.

PMID:
31022049
13.

The Role of Particle Therapy for the Treatment of Skull Base Tumors and Tumors of the Central Nervous System (CNS).

Diehl CD, Halasz LM, Wilkens JJ, Grosu AL, Combs SE.

Top Magn Reson Imaging. 2019 Apr;28(2):49-61. doi: 10.1097/RMR.0000000000000197. Review.

PMID:
31022048
14.

Retroperitoneal soft tissue sarcoma: low-dose neoadjuvant radiation therapy followed by surgery with or without intraoperative radiotherapy and adjuvant radiation therapy.

Kirste S, Landenberger N, Scholber J, Henne K, Wittel UA, Grosu AL.

Strahlenther Onkol. 2019 Jun;195(6):558-565. doi: 10.1007/s00066-019-01464-3. Epub 2019 Apr 10.

PMID:
30972454
15.

The Therapeutic Potential of Mesenchymal Stromal Cells in the Treatment of Chemotherapy-Induced Tissue Damage.

Rühle A, Lopez Perez R, Zou B, Grosu AL, Huber PE, Nicolay NH.

Stem Cell Rev Rep. 2019 Jun;15(3):356-373. doi: 10.1007/s12015-019-09886-3. Review.

PMID:
30937640
16.

Management of patients with brain metastases from non-small cell lung cancer and adverse prognostic features: multi-national radiation treatment recommendations are heterogeneous.

Nieder C, Guckenberger M, Gaspar LE, Rusthoven CG, De Ruysscher D, Sahgal A, Nguyen T, Grosu AL, Mehta MP.

Radiat Oncol. 2019 Feb 15;14(1):33. doi: 10.1186/s13014-019-1237-9.

17.

Combination of stereotactic radiotherapy and targeted therapy: patterns-of-care survey in German-speaking countries.

Kroeze SGC, Fritz C, Basler L, Gkika E, Brunner TB, Grosu AL, Guckenberger M.

Strahlenther Onkol. 2019 Mar;195(3):199-206. doi: 10.1007/s00066-018-01422-5. Epub 2019 Feb 8.

PMID:
30737541
18.

QRS fragmentation as possible new marker of fibrosis in patients with myocarditis. Preliminary validation with cardiac magnetic resonance.

Ferrero P, Piazza I, Grosu A, Brambilla P, Sironi S, Senni M.

Eur J Heart Fail. 2019 Sep;21(9):1160-1161. doi: 10.1002/ejhf.1413. Epub 2019 Feb 4. No abstract available.

PMID:
30714659
19.

ICRU report 91 on prescribing, recording, and reporting of stereotactic treatments with small photon beams : Statement from the DEGRO/DGMP working group stereotactic radiotherapy and radiosurgery.

Wilke L, Andratschke N, Blanck O, Brunner TB, Combs SE, Grosu AL, Moustakis C, Schmitt D, Baus WW, Guckenberger M.

Strahlenther Onkol. 2019 Mar;195(3):193-198. doi: 10.1007/s00066-018-1416-x. Epub 2019 Jan 16. Review.

PMID:
30649567
20.

Oncogenic transgelin-2 is differentially regulated in isocitrate dehydrogenase wild-type vs. mutant gliomas.

Beyer SJ, Bell EH, McElroy JP, Fleming JL, Cui T, Becker A, Bassett E, Johnson B, Gulati P, Popp I, Staszewski O, Prinz M, Grosu AL, Haque SJ, Chakravarti A.

Oncotarget. 2018 Dec 14;9(98):37097-37111. doi: 10.18632/oncotarget.26365. eCollection 2018 Dec 14.

21.

Early Impact of Pulmonary Fractionated Stereotactic Body Radiotherapy on Quality of Life:Benefit for Patients With Low Initial Scores (STRIPE Trial).

Adebahr S, Hechtner M, Schräder N, Schimek-Jasch T, Kaier K, Duncker-Rohr V, Gkika E, Momm F, Gaertner J, Becker G, Grosu AL, Nestle U.

J Thorac Oncol. 2019 Mar;14(3):408-419. doi: 10.1016/j.jtho.2018.10.170. Epub 2018 Dec 3.

PMID:
30521969
22.

Digital Follow-Up and the Perspective of Patient-Centered Care in Oncology: What's the PROblem?

Giordano FA, Welzel G, Siefert V, Jahnke L, Ganslandt T, Wenz F, Grosu AL, Heinemann F, Nicolay NH.

Oncology. 2018 Dec 5:1-7. doi: 10.1159/000495294. [Epub ahead of print] Review.

23.

Repeated SBRT for in- and out-of-field recurrences in the liver.

Gkika E, Strouthos I, Kirste S, Adebahr S, Schultheiss M, Bettinger D, Fritsch R, Brass V, Maruschke L, Neeff HP, Lang SA, Nestle U, Grosu AL, Brunner TB.

Strahlenther Onkol. 2019 Mar;195(3):246-253. doi: 10.1007/s00066-018-1385-0. Epub 2018 Oct 23.

PMID:
30353350
24.

Correction to: Effect of radiochemotherapy on T2* MRI in HNSCC and its relation to FMISO PET derived hypoxia and FDG PET.

Wiedenmann N, Bunea H, Rischke HC, Bunea A, Majerus L, Bielak L, Protopopov A, Ludwig U, Büchert M, Stoykow C, Nicolay NH, Weber WA, Mix M, Meyer PT, Hennig J, Bock M, Grosu AL.

Radiat Oncol. 2018 Sep 21;13(1):183. doi: 10.1186/s13014-018-1134-7.

25.

Is mild asymptomatic left ventricular systolic dysfunction always predictive of adverse events in high-risk populations? Insights from the DAVID-Berg study.

Gori M, Redfield MM, Calabrese A, Canova P, Cioffi G, De Maria R, Grosu A, Fontana A, Iacovoni A, Ferrari P, Parati G, Gavazzi A, Senni M.

Eur J Heart Fail. 2018 Nov;20(11):1540-1548. doi: 10.1002/ejhf.1298. Epub 2018 Sep 17.

PMID:
30225956
26.

Diffusion-weighted MRI and ADC versus FET-PET and GdT1w-MRI for gross tumor volume (GTV) delineation in re-irradiation of recurrent glioblastoma.

Popp I, Bott S, Mix M, Oehlke O, Schimek-Jasch T, Nieder C, Nestle U, Bock M, Yuh WTC, Meyer PT, Weber WA, Urbach H, Mader I, Grosu AL.

Radiother Oncol. 2019 Jan;130:121-131. doi: 10.1016/j.radonc.2018.08.019. Epub 2018 Sep 12.

PMID:
30219612
27.

Mathematical Description of Changes in Tumour Oxygenation from Repeated Functional Imaging.

Lazzeroni M, Bunea H, Grosu AL, Baltas D, Toma-Dasu I, Dasu A.

Adv Exp Med Biol. 2018;1072:195-200. doi: 10.1007/978-3-319-91287-5_31.

PMID:
30178345
28.

Proteome Profiling of Primary Pancreatic Ductal Adenocarcinomas Undergoing Additive Chemoradiation Link ALDH1A1 to Early Local Recurrence and Chemoradiation Resistance.

Oria VO, Bronsert P, Thomsen AR, Föll MC, Zamboglou C, Hannibal L, Behringer S, Biniossek ML, Schreiber C, Grosu AL, Bolm L, Rades D, Keck T, Werner M, Wellner UF, Schilling O.

Transl Oncol. 2018 Dec;11(6):1307-1322. doi: 10.1016/j.tranon.2018.08.001. Epub 2018 Aug 30.

29.

A Five-MicroRNA Signature Predicts Survival and Disease Control of Patients with Head and Neck Cancer Negative for HPV Infection.

Hess J, Unger K, Maihoefer C, Schüttrumpf L, Wintergerst L, Heider T, Weber P, Marschner S, Braselmann H, Samaga D, Kuger S, Pflugradt U, Baumeister P, Walch A, Woischke C, Kirchner T, Werner M, Werner K, Baumann M, Budach V, Combs SE, Debus J, Grosu AL, Krause M, Linge A, Rödel C, Stuschke M, Zips D, Zitzelsberger H, Ganswindt U, Henke M, Belka C.

Clin Cancer Res. 2019 Mar 1;25(5):1505-1516. doi: 10.1158/1078-0432.CCR-18-0776. Epub 2018 Aug 31.

PMID:
30171046
30.

Effect of radiochemotherapy on T2* MRI in HNSCC and its relation to FMISO PET derived hypoxia and FDG PET.

Wiedenmann N, Bunea H, Rischke HC, Bunea A, Majerus L, Bielak L, Protopopov A, Ludwig U, Büchert M, Stoykow C, Nicolay NH, Weber WA, Mix M, Meyer PT, Hennig J, Bock M, Grosu AL.

Radiat Oncol. 2018 Aug 29;13(1):159. doi: 10.1186/s13014-018-1103-1. Erratum in: Radiat Oncol. 2018 Sep 21;13(1):183.

31.

Comparison of local tumor control in patients with HCC treated with SBRT or TACE: a propensity score analysis.

Bettinger D, Gkika E, Schultheiss M, Glaser N, Lange S, Maruschke L, Buettner N, Kirste S, Nestle U, Grosu AL, Thimme R, Brunner TB.

BMC Cancer. 2018 Aug 9;18(1):807. doi: 10.1186/s12885-018-4696-8.

32.

Outcome after PSMA PET/CT based salvage radiotherapy in patients with biochemical recurrence after radical prostatectomy: a bi-institutional retrospective analysis.

Schmidt-Hegemann NS, Stief C, Kim TH, Eze C, Kirste S, Strouthos I, Li M, Schultze-Seemann W, Ilhan H, Fendler WP, Bartenstein P, Grosu AL, Ganswindt U, Belka C, Meyer PT, Zamboglou C.

J Nucl Med. 2018 Jul 12. pii: jnumed.118.212563. doi: 10.2967/jnumed.118.212563. [Epub ahead of print]

33.

Beneficial effects of adaptive servo-ventilation on natriuretic peptides and diastolic function in acute heart failure patients with preserved ejection fraction and sleep-disordered breathing.

D'Elia E, Ferrero P, Vittori C, Iacovoni A, Grosu A, Gori M, Duino V, Perlini S, Senni M.

Sleep Breath. 2019 Mar;23(1):287-291. doi: 10.1007/s11325-018-1681-z. Epub 2018 Jun 15.

PMID:
29948858
34.

Clinical Presentation and Outcome in a Contemporary Cohort of Patients With Acute Myocarditis.

Ammirati E, Cipriani M, Moro C, Raineri C, Pini D, Sormani P, Mantovani R, Varrenti M, Pedrotti P, Conca C, Mafrici A, Grosu A, Briguglia D, Guglielmetto S, Perego GB, Colombo S, Caico SI, Giannattasio C, Maestroni A, Carubelli V, Metra M, Lombardi C, Campodonico J, Agostoni P, Peretto G, Scelsi L, Turco A, Di Tano G, Campana C, Belloni A, Morandi F, Mortara A, Cirò A, Senni M, Gavazzi A, Frigerio M, Oliva F, Camici PG; Registro Lombardo delle Miocarditi.

Circulation. 2018 Sep 11;138(11):1088-1099. doi: 10.1161/CIRCULATIONAHA.118.035319.

35.

Prognostic and predictive factors in patients with brain metastases from solid tumors: A review of published nomograms.

Nieder C, Mehta MP, Geinitz H, Grosu AL.

Crit Rev Oncol Hematol. 2018 Jun;126:13-18. doi: 10.1016/j.critrevonc.2018.03.018. Epub 2018 Mar 29. Review.

PMID:
29759555
36.

PSMA-PET based radiotherapy: a review of initial experiences, survey on current practice and future perspectives.

Zschaeck S, Lohaus F, Beck M, Habl G, Kroeze S, Zamboglou C, Koerber SA, Debus J, Hölscher T, Wust P, Ganswindt U, Baur ADJ, Zöphel K, Cihoric N, Guckenberger M, Combs SE, Grosu AL, Ghadjar P, Belka C.

Radiat Oncol. 2018 May 11;13(1):90. doi: 10.1186/s13014-018-1047-5. Review.

37.

Local control and possibility of tailored salvage after hypofractionated stereotactic radiotherapy of the cavity after brain metastases resection.

Bilger A, Bretzinger E, Fennell J, Nieder C, Lorenz H, Oehlke O, Grosu AL, Specht HM, Combs SE.

Cancer Med. 2018 Jun;7(6):2350-2359. doi: 10.1002/cam4.1486. Epub 2018 May 9.

38.

Focal dose escalation for prostate cancer using 68Ga-HBED-CC PSMA PET/CT and MRI: a planning study based on histology reference.

Zamboglou C, Thomann B, Koubar K, Bronsert P, Krauss T, Rischke HC, Sachpazidis I, Drendel V, Salman N, Reichel K, Jilg CA, Werner M, Meyer PT, Bock M, Baltas D, Grosu AL.

Radiat Oncol. 2018 May 2;13(1):81. doi: 10.1186/s13014-018-1036-8.

39.

Multicenter analysis of stereotactic radiotherapy of the resection cavity in patients with brain metastases.

Combs SE, Bilger A, Diehl C, Bretzinger E, Lorenz H, Oehlke O, Specht HM, Kirstein A, Grosu AL.

Cancer Med. 2018 Jun;7(6):2319-2327. doi: 10.1002/cam4.1477. Epub 2018 Apr 25.

40.

The dose distribution in dominant intraprostatic tumour lesions defined by multiparametric MRI and PSMA PET/CT correlates with the outcome in patients treated with primary radiation therapy for prostate cancer.

Zamboglou C, Klein CM, Thomann B, Fassbender TF, Rischke HC, Kirste S, Henne K, Volegova-Neher N, Bock M, Langer M, Meyer PT, Baltas D, Grosu AL.

Radiat Oncol. 2018 Apr 12;13(1):65. doi: 10.1186/s13014-018-1014-1. No abstract available.

41.

Clinical outcome after high-precision radiotherapy for skull base meningiomas: Pooled data from three large German centers for radiation oncology.

Combs SE, Farzin M, Boehmer J, Oehlke O, Molls M, Debus J, Grosu AL.

Radiother Oncol. 2018 May;127(2):274-279. doi: 10.1016/j.radonc.2018.03.006. Epub 2018 Mar 26.

PMID:
29598834
42.

Local control and overall survival after frameless radiosurgery: A single center experience.

Bilger A, Frenzel F, Oehlke O, Wiehle R, Milanovic D, Prokic V, Nieder C, Grosu AL.

Clin Transl Radiat Oncol. 2017 Nov 6;7:55-61. doi: 10.1016/j.ctro.2017.09.007. eCollection 2017 Dec.

43.

SDF-1/CXCR4 expression in head and neck cancer and outcome after postoperative radiochemotherapy.

De-Colle C, Mönnich D, Welz S, Boeke S, Sipos B, Fend F, Mauz PS, Tinhofer I, Budach V, Jawad JA, Stuschke M, Balermpas P, Rödel C, Grosu AL, Abdollahi A, Debus J, Bayer C, Belka C, Pigorsch S, Combs SE, Lohaus F, Linge A, Krause M, Baumann M, Zips D, Menegakis A.

Clin Transl Radiat Oncol. 2017 Jul 14;5:28-36. doi: 10.1016/j.ctro.2017.06.004. eCollection 2017 Aug.

44.

Re-irradiation of recurrent gliomas: pooled analysis and validation of an established prognostic score-report of the Radiation Oncology Group (ROG) of the German Cancer Consortium (DKTK).

Combs SE, Niyazi M, Adeberg S, Bougatf N, Kaul D, Fleischmann DF, Gruen A, Fokas E, Rödel CM, Eckert F, Paulsen F, Oehlke O, Grosu AL, Seidlitz A, Lattermann A, Krause M, Baumann M, Guberina M, Stuschke M, Budach V, Belka C, Debus J, Kessel KA.

Cancer Med. 2018 May;7(5):1742-1749. doi: 10.1002/cam4.1425. Epub 2018 Mar 23.

45.

Influence of inhomogeneous radiosensitivity distributions and intrafractional organ movement on the tumour control probability of focused IMRT in prostate cancer.

Thomann B, Sachpazidis I, Koubar K, Zamboglou C, Mavroidis P, Wiehle R, Grosu AL, Baltas D.

Radiother Oncol. 2018 Apr;127(1):62-67. doi: 10.1016/j.radonc.2018.02.006. Epub 2018 Mar 13.

PMID:
29548559
46.

Standard of Care Versus Metastases-directed Therapy for PET-detected Nodal Oligorecurrent Prostate Cancer Following Multimodality Treatment: A Multi-institutional Case-control Study.

Steuber T, Jilg C, Tennstedt P, De Bruycker A, Tilki D, Decaestecker K, Zilli T, Jereczek-Fossa BA, Wetterauer U, Grosu AL, Schultze-Seemann W, Heinzer H, Graefen M, Morlacco A, Karnes RJ, Ost P.

Eur Urol Focus. 2018 Mar 10. pii: S2405-4569(18)30077-4. doi: 10.1016/j.euf.2018.02.015. [Epub ahead of print]

PMID:
29530632
47.

Biological imaging for individualized therapy in radiation oncology: part I physical and technical aspects.

Gainey M, Carles M, Mix M, Meyer PT, Bock M, Grosu AL, Baltas D.

Future Oncol. 2018 Apr;14(8):737-749. doi: 10.2217/fon-2017-0464. Epub 2018 Mar 9.

PMID:
29521520
48.

Biological imaging for individualized therapy in radiation oncology: part II medical and clinical aspects.

Gkika E, Oehlke O, Bunea H, Wiedenmann N, Adebahr S, Nestle U, Zamboglou C, Kirste S, Fennell J, Brunner T, Gainey M, Baltas D, Langer M, Urbach H, Bock M, Meyer PT, Grosu AL.

Future Oncol. 2018 Apr;14(8):751-769. doi: 10.2217/fon-2017-0465. Epub 2018 Mar 9.

PMID:
29521519
49.

Unresectable hepatic PEComa: a rare malignancy treated with stereotactic body radiation therapy (SBRT) followed by complete resection.

Kirste S, Kayser G, Zipfel A, Grosu AL, Brunner T.

Radiat Oncol. 2018 Feb 20;13(1):28. doi: 10.1186/s13014-018-0974-5.

50.

Independent validation of a new reirradiation risk score (RRRS) for glioma patients predicting post-recurrence survival: A multicenter DKTK/ROG analysis.

Niyazi M, Adeberg S, Kaul D, Boulesteix AL, Bougatf N, Fleischmann DF, Grün A, Krämer A, Rödel C, Eckert F, Paulsen F, Kessel KA, Combs SE, Oehlke O, Grosu AL, Seidlitz A, Lattermann A, Krause M, Baumann M, Guberina M, Stuschke M, Budach V, Belka C, Debus J.

Radiother Oncol. 2018 Apr;127(1):121-127. doi: 10.1016/j.radonc.2018.01.011. Epub 2018 Feb 9.

PMID:
29433917

Supplemental Content

Support Center